Therapeutic area
Infectious Disease & Vaccines biotech companies
The 4 infectious disease & vaccines companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| MRNAModerna | mRNA-1345 (RSV) · Respiratory syncytial virus (RSV) in older adultsApproved | $6.91B2026-06-30 | — | archived |
| GILDGilead Sciences | Biktarvy · HIVApproved | $3.18B2026-06-30 | — | archived |
| BNTXBioNTech | ONC-392 · Non-small cell lung cancer (NSCLC)Phase 3 | no filing parsed | — | archived |
| PCVXVaxcyte | VAX-31 · adult invasive pneumococcal disease preventionPhase 3 | no filing parsed | — | archived |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2027-01 · PCVX · VAX-31 immunobridging: VAX-31 in Pneumococcal disease, adults 50+ — primary completion ClinicalTrials.gov
- 2027-03 · PCVX · VAX-31 concomitant SIV: VAX-31 in Pneumococcal disease with influenza vaccine — primary completion ClinicalTrials.gov
- 2027-12 · PCVX · VAX-31 infant dose-finding: VAX-31 in Pneumococcal disease, infants — primary completion ClinicalTrials.gov
- 2031-05 · GILD · KITE-753 vs axi-cel: KITE-753 in Relapsed/refractory large B-cell lymphoma — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.